Albert David Ltd
Albert David Ltd is engaged in manufacturing and trading of Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms and Bulk Drugs by way of domestic sale or export.[1]
- Market Cap ₹ 669 Cr.
- Current Price ₹ 1,172
- High / Low ₹ 1,608 / 554
- Stock P/E 10.1
- Book Value ₹ 614
- Dividend Yield 0.77 %
- ROCE 17.0 %
- ROE 12.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 35.0% CAGR over last 5 years
Cons
- The company has delivered a poor sales growth of 3.64% over past five years.
- Company has a low return on equity of 11.5% over last 3 years.
- Earnings include an other income of Rs.47.1 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
228 | 261 | 287 | 317 | 318 | 293 | 285 | 316 | 320 | 246 | 313 | 341 | 355 | |
204 | 236 | 254 | 281 | 286 | 266 | 267 | 286 | 289 | 227 | 272 | 297 | 308 | |
Operating Profit | 24 | 26 | 33 | 37 | 31 | 27 | 18 | 30 | 30 | 19 | 41 | 44 | 47 |
OPM % | 11% | 10% | 11% | 12% | 10% | 9% | 6% | 10% | 10% | 8% | 13% | 13% | 13% |
1 | 2 | 1 | 2 | 43 | 8 | 9 | 15 | 7 | 17 | 16 | 15 | 47 | |
Interest | 4 | 4 | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
Depreciation | 10 | 11 | 11 | 15 | 9 | 8 | 8 | 7 | 8 | 8 | 9 | 9 | 7 |
Profit before tax | 11 | 13 | 18 | 20 | 63 | 26 | 18 | 38 | 29 | 27 | 47 | 51 | 86 |
Tax % | 32% | 36% | 32% | 32% | 24% | 39% | 45% | 29% | 34% | 19% | 25% | 29% | |
8 | 9 | 13 | 14 | 48 | 16 | 10 | 27 | 19 | 22 | 35 | 36 | 66 | |
EPS in Rs | 13.37 | 15.00 | 22.02 | 24.00 | 84.10 | 27.96 | 17.24 | 46.68 | 33.59 | 38.79 | 61.78 | 63.38 | 116.07 |
Dividend Payout % | 34% | 30% | 23% | 23% | 7% | 20% | 32% | 13% | 21% | 15% | 15% | 14% |
Compounded Sales Growth | |
---|---|
10 Years: | 3% |
5 Years: | 4% |
3 Years: | 2% |
TTM: | 6% |
Compounded Profit Growth | |
---|---|
10 Years: | 16% |
5 Years: | 35% |
3 Years: | 24% |
TTM: | 81% |
Stock Price CAGR | |
---|---|
10 Years: | 25% |
5 Years: | 25% |
3 Years: | 38% |
1 Year: | 94% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 11% |
3 Years: | 12% |
Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
Reserves | 70 | 75 | 85 | 87 | 131 | 177 | 180 | 205 | 217 | 239 | 274 | 306 | 345 |
40 | 38 | 42 | 30 | 20 | 30 | 28 | 0 | 2 | 2 | 6 | 5 | 1 | |
88 | 64 | 66 | 71 | 67 | 71 | 76 | 84 | 95 | 95 | 116 | 106 | 103 | |
Total Liabilities | 203 | 183 | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 455 |
69 | 72 | 67 | 49 | 44 | 87 | 83 | 77 | 91 | 84 | 88 | 80 | 79 | |
CWIP | 6 | 1 | 3 | 5 | 5 | 9 | 5 | 5 | 2 | 1 | 1 | 3 | 9 |
Investments | 0 | 0 | 16 | 16 | 48 | 59 | 68 | 113 | 122 | 138 | 183 | 193 | 225 |
127 | 110 | 111 | 122 | 127 | 130 | 134 | 99 | 106 | 119 | 130 | 148 | 142 | |
Total Assets | 203 | 183 | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 455 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
11 | 20 | 21 | 28 | 68 | 20 | 30 | 32 | 30 | 37 | 40 | 11 | |
-12 | -9 | -24 | -9 | -38 | -36 | -11 | -19 | -20 | -37 | -40 | -5 | |
-11 | -8 | -2 | -18 | -18 | 7 | -5 | -17 | -10 | -2 | -2 | -6 | |
Net Cash Flow | -12 | 3 | -5 | 1 | 12 | -10 | 15 | -4 | 0 | -2 | -1 | -1 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 48 | 52 | 54 | 47 | 41 | 41 | 35 | 25 | 34 | 29 | 29 | 32 |
Inventory Days | 189 | 165 | 191 | 176 | 187 | 217 | 173 | 151 | 148 | 151 | 124 | 150 |
Days Payable | 146 | 110 | 135 | 103 | 102 | 117 | 127 | 102 | 132 | 104 | 96 | 95 |
Cash Conversion Cycle | 90 | 107 | 111 | 120 | 126 | 141 | 81 | 74 | 50 | 76 | 57 | 87 |
Working Capital Days | 55 | 61 | 57 | 52 | 48 | 61 | 45 | 22 | 18 | -8 | -29 | 18 |
ROCE % | 16% | 14% | 18% | 18% | 17% | 15% | 7% | 18% | 14% | 12% | 17% | 17% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
- Notice Issued To Shareholders 2d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 Apr - Notice of Postal Ballot & E-voting Information published on 17.04.2024 in English (Financial Express, All India) & Vernacular (Aajkal, West Bengal).
- Certificate Of Compliance Under Regulation 40(9) Of SEBI Listing Regulations 2015 For The Year Ended 31.03.2024. 16 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Offerings
The company offers a wide range of formulations under its various brands in the domestic market[1]
Its placental-based formulation, Placentrex, is the only human placenta-based product in India developed through indigenous research. It has emerged as the market leader in this segment and has a process patent over Placentrex. The product portfolio is largely restricted to acute therapeutic segments such as antibacterials, anti-infectives, and placental extracts. [2]